Results 61 to 70 of about 2,530 (165)

Stimuli‐responsive systems: A focus on controlled drug delivery for posterior segment ocular disease

Responsive Materials, Volume 3, Issue 4, November 2025.
This review highlights recent advances in stimuli‐responsive drug delivery for posterior segment diseases, focusing on mechanisms and potential. It also explores mechanically interlocked molecules and bioorthogonal reactions as novel approaches. Challenges and future perspectives are discussed, aiming to bridge the gap between research and clinical ...
Chengzhi Zhang, Jiayi Hou, Yameng Zhao, Yiwen Wang, Kexin Wang, Siyu Li, Yange Wang, Jiehao Zhang, Shenao Ding, Chenxu Zhang, Zongming Song, Ye Tao   +11 more
wiley   +1 more source

Efficacy and safety of brolucizumab versus aflibercept in patients with neovascular age-related macular degeneration: a randomized trial in Indian patients

International Journal of Retina and Vitreous, 2022
Background The current standard treatment for neovascular age-related macular degeneration (nAMD) involves intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) agents.
Sanjay Kumar Mishra, Pradeep Kumar, Srishti Khullar, Amrita Joshi, Alok Sati, Sonali Vinay Kumar, Deepesh Unni, Atul Kumar   +7 more
doaj   +1 more source

Sustained Disease Control in DME Patients upon Treatment Cessation with Brolucizumab. [PDF]

Background: Treatment cessation due to a dry retina has not been systematically addressed in diabetic macular edema (DME). In three out of four patients receiving 6 mg of brolucizumab in the KITE study, treatment was terminated after the study ended ...
Garweg, Justus G, Steinhauer, Sonja
core   +1 more source

Comparative efficacy of intravitreal anti‐VEGF therapy for neovascular age‐related macular degeneration: A systematic review with network meta‐analysis

Acta Ophthalmologica, Volume 103, Issue 7, Page 741-763, November 2025.
Abstract The aim of this review was to evaluate the comparative efficacy of intravitreal anti‐vascular endothelial growth factor (anti‐VEGF) therapy for neovascular AMD. We searched 12 literature databases for randomised clinical trials (RCT) on anti‐VEGF therapy for neovascular AMD and extracted data on: change from baseline to 12 months in best ...
Emilie T. S. Butler, Andreas Arnold‐Vangsted, Marianne G. Schou, Rodrigo Anguita, Jakob Bjerager, Enrico Borrelli, Lasse J. Cehofski, Lorenzo Ferro Desideri, Elon H. C. van Dijk, Carsten Faber, Jakob Grauslund, Javad N. Hajari, Josef Huemer, Oliver N. Klefter, Marie Krogh Nielsen, M. Cem Sabaner, Miklos Schneider, Yousif Subhi   +17 more
wiley   +1 more source

Brolucizumab versus aflibercept for recalcitrant diabetic macular edema in Indian real-world scenario – The BRADIR study

American Journal of Ophthalmology Case Reports
Purpose: To compare the safety and efficacy of aflibercept with brolucizumab for recalcitrant diabetic macular edema (DME). Observations: At week 52, no significant visual improvement was noted in the eyes treated with either brolucizumab (P = 0.527) or ...
Debdulal Chakraborty, Ashish Sharma, Soumen Mondal, Jay Sheth, Tushar Kanti Sinha, Subhendu Boral, Angshuman Mukherjee, Ranabir Bhattacharya, Ritobroto Maitra   +8 more
doaj   +1 more source

One-Year and 18-Month Outcomes in nAMD Patient Eyes Switched to Brolucizumab Alone versus to Brolucizumab Alternating with Other Anti-VEGF Agents

Clinical Ophthalmology, 2023
Joseph M Coney,1 Jasmyne E McCoy,1 Samriddhi Buxy Sinha,2 Nina Sonbolian,2 Lujia Zhou,3 Thomas P Hull,1 Shawn A Lewis,1 David G Miller,1 Michael A Novak,1 Scott D Pendergast,1 Hang Pham,1 Sean M Platt,1 Llewelyn J Rao,1 Jerome P Schartman,1 Lawrence J ...
Coney JM, McCoy JE, Buxy Sinha S, Sonbolian N, Zhou L, Hull TP, Lewis SA, Miller DG, Novak MA, Pendergast SD, Pham H, Platt SM, Rao LJ, Schartman JP, Singerman LJ, Donkor R, Fink M, Zubricky R, Karcher H   +18 more
doaj  

Anti-VEGF Drugs Dynamics: Relevance for Clinical Practice

Pharmaceutics, 2022
Background: A drug and disease assessment model was used to evaluate the impact of different treatment regimens on intravitreal ranibizumab, bevacizumab, aflibercept, and brolucizumab concentrations and the proportion of free vascular endothelial growth ...
Daniele Veritti, Valentina Sarao, Gianluca Gorni, Paolo Lanzetta   +3 more
doaj   +1 more source

Drug Delivery Technologies for the Treatment of Age‐Related Macular Degeneration

Advanced Science, Volume 12, Issue 39, October 20, 2025.
There are multiple therapeutic agents available for the treatment of both dry age‐related macular degeneration (AMD) and wet AMD. It is essential to continue innovation by introducing new drug delivery technologies that can incorporate those along with patient compliance and the accessibility of the technology into the early stages of research and ...
J Jesus Rodriguez‐Cruz, Jessica Cutrufello, Michael Lam, Shreya Nallaparaju, Nicholas A. Peppas   +4 more
wiley   +1 more source

Dual acting therapeutic proteins for intraocular use [PDF]

, 2020
Antibody-based medicines that target vascular endothelial growth factor (VEGF) are administered by intravitreal injection to treat chronic neovascular retinal diseases.
Awwad, S., Awwad, S., Brocchini, S., Brocchini, S., Collins, M., Collins, M., Guiliano, D., Guiliano, D., Ibeanu, N., Ibeanu, N., Khalili, H., Khalili, H., Khaw, P. T., Khaw, P. T.   +13 more
core   +1 more source

Recent Advancements in the Treatment of Age‐Related Macular Degeneration

Med Research, Volume 1, Issue 2, Page 151-169, September 2025.
ABSTRACT Age‐related macular degeneration (AMD) is a prevalent cause of visual impairment and blindness among the elderly. AMD can be categorized into two subtypes: “wet” and “dry.” Current treatments for wet AMD mainly involve anti‐vascular endothelial growth factor (VEGF) drugs, and there are three U.S.
Shan Liu, Danyang Lv, Junran Sun, Huixun Jia, Fang Zheng, Felipe Pereira, Siddharth Narendran, Zhenyu Dong, Haiyun Liu, Shunxiang Gao, Peirong Huang   +10 more
wiley   +1 more source